These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 25365419)
1. Zidovudine as modern day salvage therapy for HIV infection. Kupiec KE; Johnson JW; Barroso LF; Wrenn RH; Williamson JC AIDS Patient Care STDS; 2014 Nov; 28(11):570-4. PubMed ID: 25365419 [TBL] [Abstract][Full Text] [Related]
2. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476 [TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735 [TBL] [Abstract][Full Text] [Related]
4. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418 [TBL] [Abstract][Full Text] [Related]
5. Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study. Thuppal SV; Wanke CA; Noubary F; Cohen JT; Mwamburi M; Ooriapdickal AC; Muliyil J; Kang G; Varghese GM; Rupali P; Karthik R; Sathasivam R; Clarance P; Pulimood SA; Peter D; George L Trans R Soc Trop Med Hyg; 2015 Jun; 109(6):379-85. PubMed ID: 25778734 [TBL] [Abstract][Full Text] [Related]
6. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142 [TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086 [TBL] [Abstract][Full Text] [Related]
9. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK; N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366 [TBL] [Abstract][Full Text] [Related]
10. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023 [TBL] [Abstract][Full Text] [Related]
11. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320 [TBL] [Abstract][Full Text] [Related]
12. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. Katzenstein DA; Hughes M; Albrecht M; Hammer S; Para M; Murphy R; Valdez H; Haubrich R; Liou S AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1031-7. PubMed ID: 10933617 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM; Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206 [TBL] [Abstract][Full Text] [Related]
14. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228 [TBL] [Abstract][Full Text] [Related]
15. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E; Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872 [TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria. Meloni ST; Chang CA; Eisen G; Jolayemi T; Banigbe B; Okonkwo PI; Kanki PJ PLoS One; 2016; 11(10):e0164030. PubMed ID: 27764094 [TBL] [Abstract][Full Text] [Related]
17. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE; HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008 [TBL] [Abstract][Full Text] [Related]
18. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B; HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978 [TBL] [Abstract][Full Text] [Related]
19. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465 [TBL] [Abstract][Full Text] [Related]
20. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]